TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01469793

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DMOT4039A
Description: DMOT4093A will be administered by intravenous infusion on either a Q3W or a Q1W dosing schedule, in 21-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DMOT4039A
Description: DMOT4093A will be administered by intravenous infusion on either a Q3W or a Q1W dosing schedule, in 21-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DMOT4039A
Description: DMOT4093A will be administered by intravenous infusion on either a Q3W or a Q1W dosing schedule, in 21-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DMOT4039A
Description: DMOT4093A will be administered by intravenous infusion on either a Q3W or a Q1W dosing schedule, in 21-day cycles.
Study: NCT04625478

Intervention type: OTHER
Intervention: Patients having had an osteo-articular infection with Stahylococcus
Description: Immunostaining targeting staphylococci and components will be performed on tissue samples collected from patients with osteo-articular infection
Study: NCT02148718

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: adalimumab
Description: Adalimumab pre-filled syringe, administered by subcutaneous injection
Study: NCT02210910

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: InSpace™ system over repair

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Best Repair of torn Rotator Cuff
Study: NCT04200391

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Very low carbohydrate diet
Description: All meals will be delivered and participants will consume study foods exclusively. Participants will receive a fiber supplement with each meal as needed to promote digestive health, and a daily multi-vitamin, magnesium and omega-3 supplement to ascertain micronutrient sufficiency. Participants will be weighed at each study visit and the diet plan will be adjusted for satiety and weight-maintenance.~The diet composition will be as follows: 5% carbohydrate, 75% fat, 20% protein.
Study: NCT05128292

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: CoQ10 plus Selenium
Description: 400 mg/day CoQ10 soft gel capsula (Bio-Quinone active 100 mg b.i.d) plus 200 microgram organic selenium yeast tablet (SelenoPrecise 100 microgram b.i.d.) over 8 weeks
Study: NCT01672450

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intratumoral Ipilimumab and Interleukin-2
Description: Only 1 lesion, 0.5 -2 cm, will be treated. Interleukin-2, 3 mIU IT TIW x 2 weeks (days 1, 3 and 5), then BIW x 6 weeks (days 1 and 4). Escalating doses of Ipilimumab (0.1, 0.25, 0.5, 1, 2, mg) IT weekly x 8 weeks
Study: NCT03873246

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OC-01 0.1% 0.6 mg/ml
Description: OC-01 (varenicline) nasal spray: 0.1 % (0.6 mg/ml)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OC-01 (varenicline) nasal spray: 0.2 % (1.2 mg/ml)
Description: OC-01 (varenicline) nasal spray: 0.2 % (1.2 mg/ml)
Study: NCT02660580

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Humira®
Description: Participants received EU-Humira subcutaneously in EU-Humira, EU-Humira/EU-Humira and EU-Humira/MSB11022 arm.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Humira®
Description: Participants received EU-Humira subcutaneously in EU-Humira, EU-Humira/EU-Humira and EU-Humira/MSB11022 arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Humira®
Description: Participants received EU-Humira subcutaneously in EU-Humira, EU-Humira/EU-Humira and EU-Humira/MSB11022 arm.
Study: NCT03873246

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo comparator
Description: vehicle control
Study: NCT02314221

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exoskeletal-assisted walking (ReWalk, Ekso)
Description: The WALK arm will consist of supervised exoskeletal-assisted walking training, three sessions per week (4-6 h/week) for 36 sessions (12 weeks) and usual activities for their second 12-week period.
Study: NCT03464448

Intervention type: DRUG
Intervention: Teriflunomide
Description: AUBAGIO® (teriflunomide) is a prescription medicine used to treat relapsing forms of multiple sclerosis (MS), which inhibits pyrimidine de novo synthesis by blocking the enzyme dihydroorotate dehydrogenase.
Study: NCT04015765

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hybrid Argon Plasma Coagulation and EMR procedure
Description: Hybrid Argon Plasma Coagulation (h-APC) combines an ablation technique (APC) with the option for submucosal saline injection using a high-pressure water jet. The technique allows to lift dysplastic epithelium thus creating a safety cushion under the mucosa is lifted with a saline injection and then to ablate larger areas more thoroughly and with a higher energy setting, with a low risk for side effects or complications
Study: NCT02372162

Intervention type: OTHER
Intervention: Image Fingerprint
Description: This is an observational study that uses in depth diagnostic procedures to characterize patients with a comprehensive Image Fingerprint that includes CT, MRI and PET diagnostics

Intervention type: OTHER
Intervention: Image Fingerprint
Description: This is an observational study that uses in depth diagnostic procedures to characterize patients with a comprehensive Image Fingerprint that includes CT, MRI and PET diagnostics

Intervention type: OTHER
Intervention: Molecular Fingerprint
Description: This is an observational study that uses in depth diagnostic procedures to characterize patients with a Molecular Fingerprint that includes next-generation sequencing

Intervention type: OTHER
Intervention: Molecular Fingerprint
Description: This is an observational study that uses in depth diagnostic procedures to characterize patients with a Molecular Fingerprint that includes next-generation sequencing
Study: NCT01046149

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breathing training
Description: Respiratory sinus arrhythmia biofeedback-assisted deep breathing training

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stress management
Description: Cognitive reconstructive strategies for stress management
Study: NCT03808207

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary counseling and DHA dietary increase in breastfeeding mothers
Description: Specific dietary advices in order to increase the daily/weekly intake of docosahexaenoic acid of breastfeeding mothers for the first 3 months after delivery
Study: NCT03604328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PA5108
Description: single ocular implant, administered on day 1
Study: NCT03429647

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: visible light spectroscopy
Description: Sigmoid perfusion was assessed using visible light spectroscopy
Study: NCT00815724

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Distributed Asthma Learning Initiative (DALI) distance learning program
Description: Participants will take part in two Webinar teleconferences, have access to an interactive Web site, and receive a CD-ROM of study materials and a toolkit.
Study: NCT05305690

Intervention type: OTHER
Intervention: No intervention
Description: This study did is a retrospective case series and does not involve an intervention. Investigators will compare patients managed operatively vs nonoperatively, focused on nonoperative therapy.

Intervention type: OTHER
Intervention: No intervention
Description: This study did is a retrospective case series and does not involve an intervention. Investigators will compare patients managed operatively vs nonoperatively, focused on nonoperative therapy.
Study: NCT00705666

Intervention type: BIOLOGICAL
Intervention: Peginterferon alfa-2b (SCH 54031)
Description: Peginterferon alfa-2b as monotherapy or in combination with ribavirin will be administered according to the products' labeling.

Intervention type: DRUG
Intervention: Ribavirin (SCH 18908)
Description: Peginterferon alfa-2b as monotherapy or in combination with ribavirin will be administered according to the products' labeling.
Study: NCT02286466

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education Program
Description: Participants in the control group will receive a health education program using a tablet computer identical to the intervention group. The content of this program is adapted from a health education intervention used as the control condition for a cognitive behavioral stress and affect management intervention in a NIH-funded randomized controlled trial of a quality of life intervention for patients with advanced prostate cancer (R21CA102761, PI: Penedo). The program consists of the same number of sessions as the intervention group and includes general information about health and well-being. Specifically, control participants will learn information about topics such as healthy eating, exercise, memory and cognition, and side effects in the context of a cancer diagnosis and treatment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT Mobile Application
Description: The CBT intervention is brief, consisting of 6 modules lasting approximately 30 minutes each. Sessions focus on skills for relaxation, coping with cancer-related worries, as well as activity planning and pacing. Prior to starting the program, a trained research assistant will meet with participants in a private office setting to orient them to the software and instruct them on the use of the mobile tablet device. Once patients are comfortable with the functions and features of the mobile app, they will be encouraged to self-administer the intervention on their study-issued tablet at home and during their regularly scheduled oncology visits, for example while receiving chemotherapy infusion or waiting for a doctor's appointment or tests.
Study: NCT00250263

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: (agent for immunotherapy) Staloral
Description: Immunotherapy agent for sublingual daily use. First week (vial containing the concentration 10 IR/ml) Day 1 - 1 pressure Day 2 - 2 pressures Day 3 - 4 pressures Day 4 - 6 pressures Day 5 - 8 pressures Day 6 - 10 pressures~Second week (300 IR/ml) (vial containing the concentration 300 IR/ml) Day 7 - 1 pressure Day 8 - 2 pressures Day 9 - 4 pressures Day 10 - 6 pressures Day 11 - 8 pressures~Maintenance phase Day 12 to 364 - 8 pressures daily~The first year will be followed by a second year open label period (optional)- 8 pressures daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo for sublingual use. Same schedule used for the intervention ACTIVE group.~First week (vial containing placebo) Day 1 - 1 pressure Day 2 - 2 pressures Day 3 - 4 pressures Day 4 - 6 pressures Day 5 - 8 pressures Day 6 - 10 pressures~Second week (300 IR/ml) (vial containing placebo) Day 7 - 1 pressure Day 8 - 2 pressures Day 9 - 4 pressures Day 10 - 6 pressures Day 11 - 8 pressures~Maintenance phase Day 12 to 364 - 8 pressures daily
Study: NCT03123094

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spesolimab
Description: single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spesolimab
Description: single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spesolimab
Description: single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spesolimab
Description: single dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: single dose
Study: NCT01876992

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Study: NCT02729090

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Device: treadmill
Description: Aerobic training on a treadmill continuously with speed and wave periodization. Frequency twice per week ( 2x ) for twelve weeks. Device: treadmill.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Device: treadmill Train_Comb_aerobic
Description: Device: treadmill Train_Comb_aerobic. strength training with free weights, followed by active recovery on a treadmill with fixed intervals of 60 to 120 seconds between each workforce of series. Device: treadmill Train_Comb_aerobic
Study: NCT02308059

Intervention type: OTHER
Intervention: Ultrasonographic evaluation of nerves in diabetic patients
Description: Ultrasonographic evaluation of peripheral nerves in patients with diabetes mellitus which have peripheral neuropathy

Intervention type: OTHER
Intervention: Ultrasonographic evaluation of nerves of healthy volunteers
Description: evaluation of peripheral nerves and correlated with group I
Study: NCT04793971

Intervention type: PROCEDURE
Intervention: percutaneous paratenon release
Description: percutaneous paratenon release for chronic midportion Achilles tendinopathy
Study: NCT01237405

Intervention type: DRUG
Intervention: 99mTc-EC20
Description: Study participants underwent a one-time evaluation by FolateScan which entailed a single intravenous injection of 99mTc-EC20 (total volume of 1.0 to 2.0 ml administered over a period of 30 seconds with radioactive dose between 20 and 25 mCi). A total of three imaging scans were acquired: an early phase (at \~1 minute) SPECT/CT of both knees; a late phase (at \~60 minutes) SPECT/CT image of both knees; and a late phase (at \~80 minutes) planar image of the whole body was performed (anterior-posterior, and postero-anterior).
Study: NCT01530048

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin aspart
Description: A single bolus injection of 0.2 U/kg administered subcutaneously (s.c., under the skin) on two separate dosing visits with a wash-out period 2-15 days in-between

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin aspart
Description: A single bolus injection of 0.2 U/kg administered subcutaneously (s.c., under the skin) on two separate dosing visits with a wash-out period 2-15 days in-between
Study: NCT05519943

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Friends program
Description: A GCBT intervention comprising ten weekly 60-minute sessions followed by two booster sessions
Study: NCT00205777

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bazedoxifene Acetate
Description: BZA 20mg, daily, oral

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, daily, oral
Study: NCT00230815

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Follitropin alfa injected by Pen device
Description: Follitropin alfa will be injected subcutaneously by Pen device at a dose of 75 International Unit (IU) and 150 IU in subjects aged 18-34 and 35-40 years, respectively, for 5 days. Dose will be adjusted on stimulation Day 6 until ovulation triggering criteria will met.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Recombinant Human Choriogonadotropin (r-hCG)
Description: Recombinant Human Choriogonadotropin (r-hCG) injection will be administered as a single dose of 250 microgram subcutaneously when at least 1 follicle, but not more than 3 follicles, reached a mean diameter greater than or equal to (\>=)17 mm and estradiol levels are approximately 150 picogram per milliliter (pg/mL) per mature follicle.
Study: NCT03563833

Intervention type: OTHER
Group type: OTHER
Intervention: Minimal Flow Anesthesia
Description: Minimal Flow Anesthesia with 0,4 L min-1

Intervention type: OTHER
Group type: OTHER
Intervention: High Flow Anesthesia
Description: High Flow Anesthesia with 2 L min-1
Study: NCT03930732

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab SAR231893
Description: Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Corticosteroid
Description: Pharmaceutical form: Inhaled Powder~Route of administration: Oral inhalation
Study: NCT02653924

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: silk suture
Description: each treatment will include 4 types of suture (as described above). all subjects will receive the same types of sutures. treatment plan is NOT influenced by the suture material used.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: vicryl suture
Description: each treatment will include 4 types of suture (as described above). all subjects will receive the same types of sutures. treatment plan is NOT influenced by the suture material used.
Study: NCT03930732

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Inhaled Corticosteroid
Description: Pharmaceutical form: Inhaled Powder~Route of administration: Oral inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Long-Acting Beta Agonist
Description: Pharmaceutical form: Inhaled Powder~Route of administration: Oral inhalation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Inhaled Long-Acting Beta Agonist
Description: Pharmaceutical form: Inhaled Powder~Route of administration: Oral inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Long-Acting Muscarinic Antagonist
Description: Pharmaceutical form: Inhaled Powder~Route of administration: Oral inhalation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Inhaled Long-Acting Muscarinic Antagonist
Description: Pharmaceutical form: Inhaled Powder~Route of administration: Oral inhalation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous
Study: NCT02653924

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: nylon suture
Description: each treatment will include 4 types of suture (as described above). all subjects will receive the same types of sutures. treatment plan is NOT influenced by the suture material used.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: polypropylene suture
Description: each treatment will include 4 types of suture (as described above). all subjects will receive the same types of sutures. treatment plan is NOT influenced by the suture material used.
Study: NCT03811418

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: administered as combined therapy with pertuzumab and vinorelbine or docetaxel.~Trastuzumab will be administered as an IV loading dose of 8 milligrams per kilogram (mg/kg) on day 1 of cycle 1 (1 cycle length = 21 days), and 6 mg/kg Q3W on day 1 of subsequent cycles until progressive disease, intolerable toxicity, or death.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: administered as combined therapy with pertuzumab and vinorelbine or docetaxel.~Trastuzumab will be administered as an IV loading dose of 8 milligrams per kilogram (mg/kg) on day 1 of cycle 1 (1 cycle length = 21 days), and 6 mg/kg Q3W on day 1 of subsequent cycles until progressive disease, intolerable toxicity, or death.
Study: NCT01289587

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity intervention
Description: 36 sessions of physical activity offered at different frequencies

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical activity intervention
Description: 36 sessions of physical activity offered at different frequencies
Study: NCT03811418

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pertuzumab
Description: administered as combined therapy with Kanjinti® and vinorelbine or docetaxel.~Pertuzumab will be administered as an IV loading dose of 840 milligrams (mg) on day 1 of cycle 1 (1 cycle length = 21 days), and 420 mg Q3W on day 1 of subsequent cycles until progressive disease, intolerable toxicity, or death.
Study: NCT05519943

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TAU condition
Description: A TAU waitlist condition during which participants received routine care services tailored to each child individually.
Study: NCT02198131

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laser therapy
Description: Undergo pulsed dye laser

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies
Study: NCT01489358

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-CHKVLP059-00-VP
Description: VRC-CHKVLP059-00-VP is a VLP vaccine that consists of the E1, E2 and capsid proteins of the Chikungunya Virus

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-CHKVLP059-00-VP
Description: VRC-CHKVLP059-00-VP is a VLP vaccine that consists of the E1, E2 and capsid proteins of the Chikungunya Virus

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-CHKVLP059-00-VP
Description: VRC-CHKVLP059-00-VP is a VLP vaccine that consists of the E1, E2 and capsid proteins of the Chikungunya Virus
Study: NCT01895179

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Time-Restricted Feeding
Description: Time-restricted feeding is a variant of intermittent fasting that involves eating all of one's calories within a few hours each day (typically 4-9 hours), followed by a daily fast of 15-20 hours.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Grazing
Description: Grazing involves eating meals spread out over the course of the day.
Study: NCT00776425

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epoetin beta
Description: Epoetin beta subcutaneously or intravenously at a dose of 150 IU per kg of body weight thrice weekly or 30000 IU once weekly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epoetin beta
Description: Epoetin beta subcutaneously or intravenously at a dose of 150 IU per kg of body weight thrice weekly or 30000 IU once weekly.
Study: NCT03811418

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: administered as combined therapy with Kanjinti® and vinorelbine or docetaxel.~Pertuzumab will be administered as an IV loading dose of 840 milligrams (mg) on day 1 of cycle 1 (1 cycle length = 21 days), and 420 mg Q3W on day 1 of subsequent cycles until progressive disease, intolerable toxicity, or death.
Study: NCT00674232

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 600 mcg misoprostol
Description: single dose of misoprostol taken orally

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Surgical treatment
Description: Either dilation and curettage or manual vacuum aspiration, as per local protocol
Study: NCT00051350

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: CARB

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CARB

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CARB
Study: NCT03811418

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: administered as combined therapy with Kanjinti® and pertuzumab.~Vinorelbine will be administered as an IV dose of 25 milligrams per kilogram (mg/kg) on days 1 and 8 of cycle 1 (1 cycle length = 21 days), and 25mg/kg up to 30 mg/kg (as per treating physician discretion) Q3W on day 1 of subsequent cycles until progressive disease, intolerable toxicity, or death.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: administered as combined therapy with Kanjinti® and pertuzumab.~Docetaxel will be administered as an IV dose of 75 milligrams per square meter (mg/m\^2) on day 1 of cycle 1 (1 cycle length = 21 days), and 75 mg/m\^2 (up to 100 mg/m\^2 as per treating physician discretion) Q3W on day 1 of subsequent cycles until progressive disease, intolerable toxicity, or death.